A thermostable mRNA vaccine against COVID-19

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorZhang, Na-Na-
Autor(es): dc.creatorLi, Xiao-Feng-
Autor(es): dc.creatorDeng, Yong-Qiang-
Autor(es): dc.creatorZhao, Hui-
Autor(es): dc.creatorHuang, Yi-Jiao-
Autor(es): dc.creatorYang, Guan-
Autor(es): dc.creatorHuang, Wei-Jin-
Autor(es): dc.creatorGao, Peng-
Autor(es): dc.creatorZhou, Chao-
Autor(es): dc.creatorZhang, Rong-Rong-
Autor(es): dc.creatorGuo, Yan-
Autor(es): dc.creatorSun, Shi-Hui-
Autor(es): dc.creatorFan, Hang-
Autor(es): dc.creatorZu, Shu-Long-
Autor(es): dc.creatorChen, Qi-
Autor(es): dc.creatorHe, Qi-
Autor(es): dc.creatorCao, Tian-Shu-
Autor(es): dc.creatorHuang, Xing-Yao-
Autor(es): dc.creatorQiu, Hong-Ying-
Autor(es): dc.creatorNie, Jian-Hui-
Autor(es): dc.creatorJiang, Yuhang-
Autor(es): dc.creatorYan, Hua-Yuan-
Autor(es): dc.creatorYe, Qing-
Autor(es): dc.creatorZhong, Xia-
Autor(es): dc.creatorXue, Xia-Lin-
Autor(es): dc.creatorZha, Zhen-Yu-
Autor(es): dc.creatorZhou, Dongsheng-
Autor(es): dc.creatorYang, Xiao-
Autor(es): dc.creatorWang, You-Chun-
Autor(es): dc.creatorYing, Bo-
Autor(es): dc.creatorQin, Cheng-Feng-
Data de aceite: dc.date.accessioned2026-02-09T11:20:19Z-
Data de disponibilização: dc.date.available2026-02-09T11:20:19Z-
Data de envio: dc.date.issued2020-08-03-
Data de envio: dc.date.issued2020-08-03-
Data de envio: dc.date.issued2019-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/42179-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S0092867420309326-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1138756-
Descrição: dc.descriptionThere has been an urgent need of vaccines against coronavirus disease 2019 (COVID-19) due to the ongoing SARS-CoV-2 pandemic. Among all approaches, messenger RNA (mRNA) -based vaccine has emerged as a rapid and versatile platform to quickly respond to such a challenge. Here, we developed a lipid-nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (termed ARCoV). Intramuscular immunization of ARCoV mRNA-LNPs elicited robust neutralizing antibodies against SARS-CoV-2 as well as Th1-biased cellular response in mice and non-human primates. Two doses of ARCoV immunization in mice conferred complete protection against the challenge of a SARS-CoV-2 mouse adapted strain. Additionally, ARCoV was manufactured in liquid formulation and can be stored at room temperature for at least one week. This novel COVID-19 mRNA vaccine, ARCoV, is currently being evaluated in phase 1 clinical trials.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceCell-
Palavras-chave: dc.subjectSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectmRNA vaccine-
Palavras-chave: dc.subjectLipid nanoparticle-
Palavras-chave: dc.subjectMouse adapted strain-
Palavras-chave: dc.subjectNon-human primate-
Título: dc.titleA thermostable mRNA vaccine against COVID-19-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.